136 related articles for article (PubMed ID: 37105997)
1. Lipid-coated mesoporous silica nanoparticles for anti-viral applications via delivery of CRISPR-Cas9 ribonucleoproteins.
LaBauve AE; Saada EA; Jones IKA; Mosesso R; Noureddine A; Techel J; Gomez A; Collette N; Sherman MB; Serda RE; Butler KS; Brinker CJ; Schoeniger JS; Sasaki D; Negrete OA
Sci Rep; 2023 Apr; 13(1):6873. PubMed ID: 37105997
[TBL] [Abstract][Full Text] [Related]
2. Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles.
Mazurov D; Ramadan L; Kruglova N
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992399
[TBL] [Abstract][Full Text] [Related]
3. Finely tuned ionizable lipid nanoparticles for CRISPR/Cas9 ribonucleoprotein delivery and gene editing.
Im SH; Jang M; Park JH; Chung HJ
J Nanobiotechnology; 2024 Apr; 22(1):175. PubMed ID: 38609947
[TBL] [Abstract][Full Text] [Related]
4. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition.
Suzuki Y; Onuma H; Sato R; Sato Y; Hashiba A; Maeki M; Tokeshi M; Kayesh MEH; Kohara M; Tsukiyama-Kohara K; Harashima H
J Control Release; 2021 Feb; 330():61-71. PubMed ID: 33333121
[TBL] [Abstract][Full Text] [Related]
6. Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR delivery.
Noureddine A; Maestas-Olguin A; Saada EA; LaBauve AE; Agola JO; Baty KE; Howard T; Sabo JK; Espinoza CRS; Doudna JA; Schoeniger JS; Butler KS; Negrete OA; Brinker CJ; Serda RE
Acta Biomater; 2020 Sep; 114():358-368. PubMed ID: 32702530
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of Gene Editing and Base Editing with Therapeutic Ribonucleoproteins through In Vivo Delivery Based on Absorptive Silica Nanoconstruct.
Kim S; Jeong YK; Cho CS; Lee S; Sohn CH; Kim JH; Jeong Y; Jo DH; Bae S; Lee H
Adv Healthc Mater; 2023 Feb; 12(4):e2201825. PubMed ID: 36326169
[TBL] [Abstract][Full Text] [Related]
8. Cytosolic delivery of CRISPR/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein.
Qiao J; Sun W; Lin S; Jin R; Ma L; Liu Y
Chem Commun (Camb); 2019 Apr; 55(32):4707-4710. PubMed ID: 30942216
[TBL] [Abstract][Full Text] [Related]
9. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing.
Wei T; Cheng Q; Min YL; Olson EN; Siegwart DJ
Nat Commun; 2020 Jun; 11(1):3232. PubMed ID: 32591530
[TBL] [Abstract][Full Text] [Related]
10. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
Li S; Song Z; Liu C; Chen XL; Han H
ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
[TBL] [Abstract][Full Text] [Related]
11. Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.
Bykonya AG; Lavrov AV; Smirnikhina SA
Mol Biotechnol; 2023 Feb; 65(2):181-195. PubMed ID: 35322386
[TBL] [Abstract][Full Text] [Related]
12. Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes.
Rathbone T; Ates I; Fernando L; Addlestone E; Lee CM; Richards VP; Cottle RN
CRISPR J; 2022 Jun; 5(3):397-409. PubMed ID: 35238624
[TBL] [Abstract][Full Text] [Related]
13. Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins.
Soares Medeiros LC; South L; Peng D; Bustamante JM; Wang W; Bunkofske M; Perumal N; Sanchez-Valdez F; Tarleton RL
mBio; 2017 Nov; 8(6):. PubMed ID: 29114029
[TBL] [Abstract][Full Text] [Related]
14. Non-viral delivery of the CRISPR/Cas system: DNA
Lin Y; Wagner E; Lächelt U
Biomater Sci; 2022 Mar; 10(5):1166-1192. PubMed ID: 35103261
[TBL] [Abstract][Full Text] [Related]
15. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.
Bloomer H; Khirallah J; Li Y; Xu Q
Adv Drug Deliv Rev; 2022 Feb; 181():114087. PubMed ID: 34942274
[TBL] [Abstract][Full Text] [Related]
17. Cas9 Ribonucleoprotein Complex Delivery: Methods and Applications for Neuroinflammation.
Campbell LA; Richie CT; Maggirwar NS; Harvey BK
J Neuroimmune Pharmacol; 2019 Dec; 14(4):565-577. PubMed ID: 31172397
[TBL] [Abstract][Full Text] [Related]
18. Carboxylated branched poly(β-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing.
Rui Y; Wilson DR; Choi J; Varanasi M; Sanders K; Karlsson J; Lim M; Green JJ
Sci Adv; 2019 Dec; 5(12):eaay3255. PubMed ID: 31840076
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
20. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
